APIMEDS PHARMACEUTICALS US, INC. Fair Value Adjustment of Warrants
APIMEDS PHARMACEUTICALS US, INC. (APUS) reported Fair Value Adjustment of Warrants of -$22.38 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-05-04.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-14
- APIMEDS PHARMACEUTICALS US, INC. fair value adjustment of warrants for the quarter ending 2025-12-31 was $0.00.
- APIMEDS PHARMACEUTICALS US, INC. fair value adjustment of warrants for the quarter ending 2025-09-30 was -$12.86K.
- APIMEDS PHARMACEUTICALS US, INC. fair value adjustment of warrants for the quarter ending 2025-06-30 was -$9.52K.
- APIMEDS PHARMACEUTICALS US, INC. fair value adjustment of warrants for fiscal 2025 was -$22.38K.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-04 | -$12.86K derived: sum of 2 quarters · filed 2026-05-04 | -$22.38K derived: sum of 3 quarters · filed 2026-08-14 | -$22.38K 10-K · filed 2026-05-04 |
| 2025-09-30 | -$12.86K 10-Q · filed 2025-11-12 | -$22.38K derived: sum of 2 quarters · filed 2026-08-14 | -$22.38K 10-Q · filed 2025-11-12 | |
| 2025-06-30 | -$9.52K 10-Q · filed 2026-08-14 | -$9.52K 10-Q · filed 2026-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |